pharmaphorum Podcast

In the first episode of the ELICIT podcast, a new series produced in partnership with Cerner Enviza, the guests discuss qualitative real-world evidence and a unique dementia project from Singapore.

Episode 45 of the pharmaphorum podcast heard from Dr Stuart Hill, how he’s seen the oncology landscape change and which of those he sees holding the most potential to improve patient outcomes.

In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals at Sandoz about the big issues in biosimilars.

This episode of the pharmaphorum podcast is the first in an occasional series focused on patient engagement that’s being led by Mark Duman, a clinician, consultant and patient advocate.

Episode 42 of the pharmaphorum podcast heard from Catherine Owen, who’s senior vice president of major markets at Bristol Myers Squibb, about the future of pharma commercialisation and communications.

Episode 41 of the pharmaphorum podcast heard from Amit Nastik about the impact of COVID-19 on pharma supply chains and how he and his team mitigated disruption to Novartis’ own operations.

As the world passes the year and a half mark of the COVID-19 pandemic, the evolving experience of the ‘new normal’ environment across the healthcare sector has brought huge changes to the way pharma engages healthcare professionals.

The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular focus on oncology.

In the latest episode of the podcast Dominic Tyer speaks with Nicola Massey, who’s Vertex’s senior country manager in the UK and Ireland.

In the latest episode of the podcast Dominic Tyer speaks with Dr Maria Ines ‘Mari’ Mitrani, chief science officer at the clinical-stage biopharmaceutical company Organicell Regenerative Medicine.